Press Release
ONCOLYS BIOPHARMA INC.
(TSE Mothers: 4588)
24 July 2017

Telomelysin®-Radiation Combination Therapy Interim Data to be Presented at the 15th Annual Meeting of JSMO

Tokyo, JAPAN: The interim data of an investigator-initiated clinical study for combination therapy with Oncolys Biopharma’s oncolytic virus Telomelysin® (OBP-301) and radiation for the treatment of esophageal cancer patients, conducted by a group of experts led by Dr. Toshiyoshi Fujiwara, Okayama University, will be presented on Thursday 27th July 2017 in Panel Discussion titled “New developing treatment for advanced esophageal cancer” in the 15th Annual Meeting of the Japanese Society of Medical Oncology (JSMO2017) which will be held in Kobe and in Okayama from 27th to 29th July, 2017.

Details of the presentation are as below:

【Panel Discussion – JSMO2017】

Time & Date: Thu 27 July 2017, 9:00 – 11:00 (Dr Fujiwara’s presentation:PD-4)
Venue: Hall B, 2nd floor, No.1 Building, Kobe International Exhibition Hall
Theme: "Multidisciplinary therapy with telomerase-specific oncolytic adenovirus for human esophageal cancer"
Speaker: Toshiyoshi Fujiwara, M.D., Ph.D., Professor & Chairman, Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

For more information, please visit the JSMO website: http://www.congre.co.jp/jsmo2017/english/index.html

# # #

About OBP-301 (Telomelysin®):
Telomelysin® is an oncolytic adenovirus in which gene is modified to be able to selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. Oncolytic
adenovirus has much potential for cancer immunotherapy because its viral replication is highly immunogenic, and oncolysis induced by such virus releases tumor epitopes and provides costimulatory danger signals. From the result of phase I clinical trial in the US, Oncolys obtained promising data showing abscopal effect in melanoma patients after single injection into one single tumor and found that not only increasing infiltration of CD8 and antigen presenting cells but diminishing Treg cells in injected tumor site. Clinical Research Status: esophageal cancer (clinical investigation and sponsor-initiated Phase I, in combination with radiotherapy, Okayama University, Japan); hepatocellular cancer (Phase I/II, with Medigen Biotechnology Corp., Taiwan/South Korea); melanoma (Phase II, USA); and solid tumors (clinical investigation, with pembrolizumab, National Cancer Centre Hospital East, Japan)

About Oncolys BioPharma Inc.: 
Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focus on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested as monotherapy in Phase I/II clinical trial in Asia and Phase II in the USA, for various solid tumors. In Japan, while Oncolys successfully enrolled the first patient in its own Phase I clinical trial for Telomelysin-radiation combination therapy in July 2017, an investigator-led clinical trial for Telomelysin-pembrolizumab combination therapy is underway at National Cancer Centre Hospital East. A novel cancer diagnostic product, TelomeScan® (OBP-401/1101), is expected to be effective as companion diagnostic tool in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Censavudine) for infectious diseases, for which it completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS.
For more information, please visit http://www.oncolys.com/en/

Oncolys BioPharma Inc.
Mie Yamazaki
Investors Relations & Corporate Communications
Tel: +81 (0) 5472 1578
Email: yamazaki@oncolys.com